BioSpace

Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program

Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug ...

Lilly Cuts Low-Dose Zepbound Price for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
Drug Store News

Eli Lilly lowers price of Zepbound single-dose vials

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per ...

Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Yahoo

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

Boxes for the medications Wegovy and Zepbound are arranged for a photograph in California on Thursday, May 8, 2025. (AP Photo/JoNel Aleccia) People taking Eli Lilly's obesity drug, Zepbound, lost ...

GLP-1 drugs have 'little or no effect' on risk of obesity-related cancers, study suggests

Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related ...
Devdiscourse

Race in Obesity Drugs Heats Up Amidst Legal Battles and Aid Crises

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...